Vaccine against pandemic strains of influenza viruses

1. An isolated recombinant adenovirus vector comprising a first heterologous polynucleotide sequence that encodes more than one avian influenza surface or envelope protein antigen from influenza strain H5, H7 and/or H9 and a second heterologous polynucleotide sequence that encodes at least one influenza internal protein.

2. The isolated recombinant adenovirus vector of claim 1 , wherein one of the avian influenza surface or envelope protein antigens comprises an avian influenza hemagglutinin (HA) antigen.

3. The isolated recombinant adenovirus vector of claim 1 , wherein the first heterologous polynucleotide sequence encodes a plurality of variants of the same HA antigen subtype selected from group consisting of H5, H7 and H9.

4. The isolated recombinant adenovirus vector of claim 1 , wherein the first heterologous polynucleotide sequence encodes a plurality of HA antigens of different HA subtypes selected from group consisting of H5, H7 and H9.

5. The isolated recombinant adenovirus vector of claim 1 , wherein one of the avian influenza surface or envelope protein antigens comprises an avian influenza neuraminidase (NA) antigen.

6. The isolated recombinant adenovirus vector of claim 1 , wherein one of the avian influenza surface or envelope protein antigens comprises an H5N1 strain antigen, an H7N7 strain antigen, or an H9N2 strain antigen.

7. The isolated recombinant adenovirus vector of claim 1 , wherein the influenza internal protein is an M1 protein, an M2 protein, an NP protein, an PB1 protein, a PB2 protein, an NS1 protein, an NS2 protein, or a combination thereof.

8. The isolated recombinant adenovirus vector of claim 1 , wherein the internal protein is of an H1N1, H2N2 or H3N2 influenza strain.

9. An immunogenic composition comprising the isolated recombinant adenovirus vector of claim 1 .

10. The immunogenic composition of claim 9 , further comprising a pharmaceutically acceptable carrier.

11. The isolated recombinant adenovirus vector of claim 1 , wherein the adenovirus vector is a human adenovirus vector.

12. The isolated recombinant adenovirus vector of claim 1 , wherein the adenovirus vector is a replication defective adenovirus vector.

13. The isolated recombinant adenovirus vector of claim 12 , wherein the replication defective adenovirus comprises a mutation in at least one of an E1 region gene and an E3 region gene.

14. The isolated recombinant adenovirus vector of claim 1 , wherein the adenovirus vector is replication competent.

15. The isolated recombinant adenovirus vector of claim 1 , wherein the adenovirus vector is a non-human adenovirus vector.

16. The isolated recombinant adenovirus vector of claim 15 , wherein the non-human adenovirus vector is a porcine adenovirus vector, a bovine adenovirus vector, a canine adenovirus vector, a murine adenovirus vector, an ovine adenovirus vector, an avian adenovirus vector or a simian adenovirus vector.

17. A method of producing an immune response against an avian influenza virus infection in a subject, the method comprising:

administering to a subject the immunogenic composition of claim 9 , thereby producing the immune response against the avian influenza virus infection in the subject.

18. The method of claim 17 , wherein the immune response is a protective or partially protective immune response against one or more avian influenza virus.

19. The method of claim 17 , comprising administering the immunogenic composition intranasally, orally, ocularly, intravenously, intramuscularly, transdermally, intradermally, or subcutaneously.

20. The method of claim 17 , wherein the subject is a human subject.

21. The method of claim 17 , wherein the subject is a bird.